An important goal for improving vaccine and immunotherapy technologies is the ability to provide further control over the specific phenotypes of T cells arising from these agents. Along these lines, frequent administration of rapamycin (Rapa), a small molecule inhibitor of the mammalian target of rapamycin (mTOR), exhibits a striking ability to polarize T cells toward central memory phenotypes (T CM ), or to suppress immune function, depending on the concentrations and other signals present during administration. T CM exhibit greater plasticity and proliferative capacity than effector memory T cells (T EFF ) and, therefore, polarizing vaccine-induced T cells toward T CM is an intriguing strategy to enhance T cell expansion and function against pathogens or tumors. Here we combined biodegradable microparticles encapsulating Rapa (Rapa MPs) with vaccines composed of soluble peptide antigens and molecular adjuvants to test if this approach allows polarization of differentiating T cells toward T CM . We show Rapa MPs modulate DC function, enhancing secretion of inflammatory cytokines at very low doses, and suppressing function at high doses. While Rapa MP treatment reduced -but did not stop -T cell proliferation in both CD4
Introduction
Most vaccines amplify immune responses elicited against foreign molecules ("antigens") associated with a pathogen, exploiting the exquisite specificity the immune system harnesses to destroy pathogens without targeting host cells. Despite the importance of these technologies, one of the arising themes for new vaccines and immunotherapies is the need for approaches that not only generate large responses, but that also program specific functions and phenotypes of these responses [1, 2] . In this study we used peptide antigen and common molecular vaccine adjuvants to study how controlled release of low doses of modulatory drugs during T cell expansion alters immune cell differentiation and enhances immune function in cells and mice.
Our studies are motivated by fascinating recent work revealing that regular, low doses of immunosuppressive drugs can be used to enhance vaccination and immunotherapy by maintaining plasticity -that is, limiting the differentiation -of T cells. Rapamycin (Rapa), and analogs of this drug, are some of the most-well studied along these lines [3, 4] . Rapa has historically played a significant role as an immunosuppressant, but this drug class targets the mTOR pathway, which is intimately involved in metabolism, cell growth, and differentiation [5, 6] . Several seminal studies demonstrate regular, systemic administration of Rapa increases the durability of expanding antigen-specific CD8 + T cells, and in particular, that the phenotypes of these cells are polarized away from effector T cells (T EFF ) and toward central memory T cells (T CM ) [7, 8] . While T EFF are needed to combat pathogenic cells, these cells become less proliferative as they differentiate from naïve T cells. In contrast, T CM are more plastic, exhibiting the highly proliferative capacity needed to rapidly generate large numbers of antigen-specific T EFF . Thus, expanding T CM against a target antigen might provide a route to generate large, durable populations of antigen-specific cells that mount potent responses by maintaining a highly proliferative characteristic. Gaining control over the processes above to direct immune cell differentiation could have a transformative impact in combating infectious disease, immune dysfunction, and cancer. Cancer, for example, is difficult to treat due to the heterogeneity of disease and the ability of tumors to metastasize, evade and suppress the immune system, and cause relapse [9] . Over the past decade, adoptive cell therapies -in which tumor-primed T cells are transferred to animals or patients -have led to the revelation that T CM are important drivers of anti-tumor immunity [10] . The high proliferation rates of T CM support rapid response against established tumors and improved protection against relapse [11] [12] [13] [14] . Unfortunately, as T CM expand, the differentiation to effector memory (T EM ) or effector (T EFF ) T cells results in reduced numbers of cells and cytokines (e.g., IL-2) to overcome the immunosuppressive tumor environment [15, 16] .
Adoptive cell therapy, cancer vaccination, and checkpoint blockade are some of the most studied emerging technologies in cancer research, and Rapa is also already being implemented clinically as a route to suppress the excess metabolic and proliferative function of cancer cells [17] [18] [19] . Newer pre-clinical studies are exploring modulation of low-doses of Rapa and other drugs to polarize T cell function during cancer vaccination in melanoma, glioblastoma, and thymoma models [20] [21] [22] [23] . However, inducing T CM in animals or people with Rapa or other drugs is hindered by short half-lives (t 1/2 = 1-2 h), the need for frequent injections (1-5 ×/day), drug hydrophobicity, and the challenge of codelivering drug cues with other vaccine components to target immune tissues such as lymph nodes (LNs), where tumor-specific T CM are primed by antigen-presenting cells (APCs) [24] . Overcoming these hurdles might enable cancer vaccines that achieve adoptive transfer-like potency without need for isolation, expansion, and reinfusion of cells from a patient.
In LNs, APCs process and present antigens to activate T and B cells. Thus, vaccines must reach LNs to generate antigen-specific responses. Importantly, the specific type of response depends intimately on the soluble factors and surface molecules encountered by immune cells during antigen presentation. This characteristic has created enormous interest in harnessing biomaterials for vaccines against disease and cancer immunotherapies by targeting LNs, controlling delivery kinetics, and minimizing toxicity [25] [26] [27] [28] . In this report, we combined common candidate vaccine formulations with polymer particles that slowly release minute doses of Rapa to test if this immunomodulator enhances immune response. We hypothesized that controlled release of low doses of Rapa during vaccination with peptide antigens and molecular adjuvants would moderate co-stimulation by APCs, alter cytokine secretion, and polarize differentiating T cells toward T CM that enhance the size and quality of vaccine response. We show that release of Rapa from polymer depots during vaccination preserves plasticity in differentiating T cells, allowing generation of antigen-specific T cells, but biasing these populations toward a central memory phenotype that enhances response in primary cell co-culture models and in mice.
Materials and methods

Peptides
Trp2 peptide (SVYDFFVWL) formulated as a disodium salt and MOG peptide (MEVGWYRSPFSRVVHLYRNGK) were synthesized by Genscript.
Particle synthesis and characterization
PLGA microparticles were synthesized using a double emulsion/solvent evaporation method previously described [26] . Briefly, an organic phase consisting of 80 mg of PLGA (Durect) dissolved in 5 mL dichloromethane was prepared. In samples encapsulating Rapa, polymer solution was added to a vial containing 2 mg of dried drug (LC Laboratories). A primary emulsion was formed by adding 500 μL of water with the organic phase followed by sonication for 30 s at 12 W. This primary emulsion was then added to 40 mL of 2% w/v polyvinyl alcohol (PVA, Sigma) and homogenized for 3 min at 16,000 rpm. Excess organic solvent was evaporated overnight under stirring. Particle formulations were passed through a 40 μm cell strainer and collected via centrifugation (5000g, 5 min, 4°C). Particles were then washed three times in in 1 mL water, with centrifugation steps (5000g, 5 min, 4°C) to collect particles in between, and resuspended in water. Particle diameter was determined using laser diffraction (Horiba LA-950). Yield was quantified by drying a known volume of particle suspensions under air, recording the weight, and back-calculating a total mass yield for each batch. To quantify Rapa loading, known masses of dried particles were dissolved in DMSO, and the absorbance at 278 nm was determined using UV/ VIS spectrophotometry. Absorbance values were compared with a standard curve of known concentrations of Rapa to calculate drug loading per mass of particles.
Dendritic cell uptake, activation and cytokine secretion
CD11c
+ cells were isolated from the spleens of 4-6 week old C57BL/ 6 mice (The Jackson Laboratory) using magnetic isolation according to the manufacturer's protocol (Miltenyi 
Transgenic T cell co-culture studies
In order to characterize the effects of Rapa MPs on CD4 and CD8 T cell responses, co-cultures consisting of wild type dendritic cells (DCs) and T cells from transgenic mice were performed. T cells were from 2D2 mice C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (The Jackson Laboratory) which have CD4 + T cell receptors specific for MOG, and from followed by incubation in CSFE at a final concentration of 5 μM for 5 min at room temperature and four washes in media. After 48 h of co-culture, cells were collected and proliferation was quantified by analysis of CSFE dilution using flow cytometry after staining with fluorescent anti-CD4 or anti-CD8 for 2D2 and Trp2 T cells, respectively.
i.LN. injection
i.LN. injection of C57BL/6 mice was performed as previously described [26, [29] [30] [31] [32] . Briefly, the hair was removed from mice using a mild depilatory cream, and then mice were injected subcutaneously (s.c.) at the tail base with a tracer dye (Evan's Blue). After allowing the tracer dye to drain to inguinal lymph nodes for 16 h, both inguinal lymph nodes were identified and injected using a 31G insulin needle containing indicated treatments in a volume of 10 μL. Soluble vaccines consisted of two injections of 5 μg CpG with 25 μg Trp2, or 25 μg OVA in model antigen studies. Soluble vaccines including rapamycin contained either 1 mg of Rapa MPs per injection (high dose) or 0.5 mg of Rapa MPs (low dose) per injection.
Tetramer and memory phenotype analysis
100 μL of peripheral blood was collected from mice by submandibular bleeding, followed by depletion of red blood cells by incubating with 750 μL of ACK lysis buffer. Cells were collected via centrifugation (800g, 5 min, 4°C) and resuspended in 750 μL of ACK lysis buffer. Following the second round of ACK lysis, cells were blocked by incubation with anti-CD16/CD32, and then stained with a tetramer specific for Trp2 (MBL). Cells were then washed twice with 1% BSA in PBS, stained with fluorescent anti-CD8, anti-CD44 and anti-CD62L, followed by two washes in 1% BSA in PBS. After resuspension in DAPI, tetramer and memory marker expression was analyzed by flow cytometry.
Tumor challenge studies
After treating mice with the indicated vaccines, mice were shaved and injected s.c. at the hind flank with 3 × 10 5 B16-F10 (ATCC) cells in 100 μL of cold PBS. Mice were then weighed and monitored for tumor growth daily following inoculation. Tumor burden was calculated as the product of two orthogonal diameters. Mice were euthanized according to the IACUC-approved humane endpoints when aggregate tumor burden reached 150 mm 2 .
Statistical analysis
One-way ANOVA with a Tukey post-test was used to compare three or more groups during in vitro and in vivo studies. Significance for survival studies was carried out with a Log-rank test. t-tests were used to compare the two groups for T CM :T EFF ratios. In all cases, analyses were carried out with Graphpad Prism (version 6.02). Error bars represent the mean ± SEM and p values were considered significant as defined by: *p b 0.05; **p b 0.01; ***p b 0.001; ****p b 0.0001.
Results
Rapa is encapsulated in PLGA MPs and slowly released over time
To test our hypothesis that low levels of Rapa promote T CM during vaccine delivery, a well-established platform, PLGA MPs, was used to encapsulate and release Rapa. Rapa MPs were formed via double emulsion and exhibited Rapa loading levels of 17.3 ± 0.68 μg rapamycin/mg particle and average diameters of 2.45 ± 0.13 μm (Fig. 1A,B) . In order to quantify drug release from Rapa MPs, MPs were incubated in water at 37°C using sink conditions. Rapa MPs released 65.2 ± 0.01% of drug over 14 days (Fig. 1C ).
MPs are internalized by primary DCs in vitro and do not cause toxicity
To test the ability of DCs to internalize MPs, MPs encapsulating fluorescent peptide and Rapa were synthesized and cultured with primary splenic DCs. After 4 h, a dose dependent uptake of MPs was measured using flow cytometry (Fig. 1D) ; uptake was visualized by microscopy after 2 h of culture and indicated co-localization of MPs within DCs membranes (Fig. 1E ). To confirm MPs were non-toxic, primary DCs were stimulated with LPS and treated with decreasing doses of Rapa MPs. After 18 h no reduction in toxicity for any of the tested doses of Rapa MPs was observed by analysis with flow cytometry after DAPI staining (Fig. 1F ).
Rapa MPs transiently decrease DC activation and modulate inflammatory cytokine secretion in a dose dependent manner
In order to investigate the effects of Rapa dose during activation of DCs, splenic CD11c + DCs were stimulated with LPS and treated with decreasing doses of soluble Rapa or Rapa MPs. DCs stimulated with LPS and treated with empty MPs at equivalent particle masses to the Rapa MP groups were included as controls in order to isolate the effect from encapsulated Rapa. After 18 h of culture, DCs treated with Rapa MPs exhibited modest decreases in expression of surface activation markers, CD40 ( Fig. 2A) , CD80 ( Fig. 2B ) and CD86 ( Fig. 2C ) compared to empty MP controls. These observed effects were transient, as DCs treated with Rapa MPs did not exhibit decreased activation 48 h after treatment (Fig. S1 ). The concentrations of IL-6, IL-12 and IFNγ in culture supernatants at 48 h were next measured to determine the effects of Rapa MPs on function, as indicated by cytokine profiles. A dosing effect was observed, where high Rapa MPs doses decreased IFNγ levels compared to untreated DCs stimulated with LPS. At these higher doses (i.e., 1, 0.1, 0.01 μg/mL), Rapa MPs significantly reduced IFNγ levels relative to empty particles; there were some non-specific effects from empty particles at high doses relative to LPS only treatment (Fig. 3A ). An intriguing dosing effect was observed with IL-12 levels (Fig. 3B ), and to a lesser extent, IL-6 (Fig. 3C ). For these cytokines, high levels of Rapa had no effect vs. LPS, whereas at intermediate Rapa MP concentrations, IL-12 and IL-6 levels peaked before returning at the lowest doses to the low cytokine levels observed for the LPS controls. No non-specific effects were observed with empty MP controls.
Rapa MPs reduce CD4 and CD8 T cell proliferation and promote central memory phenotypes in vitro
To investigate if the differential dose effects of Rapa MPs on DC cytokine secretion alter T cell proliferation and phenotype, co-culture studies were performed using DC/transgenic CD4 + T cell co-culture to assess effects on antigens presented by the MHC-II pathway, and a DC/transgenic CD8 + T cell co-culture to investigate effects on antigens presented by the MHC-I pathway. In these studies, DCs from naïve C57/BL6 mice were treated with Rapa MPs with or without LPS stimulation in the presence of a CD4 epitope, MOG, or a CD8 epitope, Trp2. T cells were then isolated from transgenic 2D2 mice, which have CD4 T cells displaying T cell receptors specific for MOG presented in MHC-II, or Trp2 transgenic mice, where CD8 T cell receptors recognize Trp2 presented in MHC-I. Isolated T cells were then cultured with DCs in the presence of their respective cognate antigens. After 48 h of co-culture, Rapa MP treatment reduced 2D2 T cell proliferation compared to empty MP controls. These effects were seen in CD4 co-cultures performed both with or without LPS stimulation (Fig. 4A,B) . Concentrations of IL-17, an inflammatory cytokine characteristic of a T H 17 polarized response were also measured in culture supernatants. In these studies, Rapa MPs decreased IL-17 secretion in 2D2 co-cultures with or without LPS stimulation (Fig. 4C,D) , indicating a suppressive function at each dose for MHC-II/CD4 co-culture. In Trp2 co-cultures (CD8), Rapa MPs also decreased T cell proliferation relative to samples treated with Trp2 and empty MP controls, but still allowed an intermediate level of proliferation relative to that observed in untreated cells (Fig. 5A,B) . Representative flow cytometry plots from the mean CSFE dilution data shown in Fig. 5A ,B confirmed that despite a decreased percentage of proliferated cells, T cells treated with Rapa MPs proliferated for multiple generations compared to T cells in empty MP treated or untreated co-cultures stimulated with LPS and Trp2 (Fig. S2) . This trend was observed in both co-cultures stimulated with LPS or co-cultures left unstimulated. Interestingly, while the magnitude of reduction in proliferation from Rapa MP treatment was similar for LPS stimulated or unstimulated co-cultures, differences were seen in IFNγ levels in culture supernatants. While in the presence of LPS, Rapa MPs only significantly suppressed IFNγ at a dose of 1 μg/mL Rapa MPs (Fig. 5C ), Rapa MPs completely suppressed IFNγ secretion in unstimulated co-cultures at all three doses (Fig. 5D) . In order to determine if Rapa MPs polarized T cells toward central memory phenotypes, CD44 and CD62L expression was quantified with flow cytometry. Rapa MPs increased the percentages of central memory phenotypes (CD8 + / CD62L + CD44 + ) in both LPS-stimulated and unstimulated co-cultures, and interestingly, this effect peaked at an intermediate Rapa MPs doses (0.1 μg/mL) (Fig. 5E,F) . In particular, while cultures stimulated with LPS and Trp2 and left untreated or treated with empty MPs exhibited low levels of CD8 T cells with central memory phenotypes (4.3 ± 0.37% and 5.83 ± 0.38%, respectively), the percentage of central memory T cells was increased to 19.57 ± 1.42% after treatment with 0.1 μg/mL Rapa MPs. Additionally, it was observed that Rapa MP treatment for both Trp2 co-cultures reduced the percentages of effector memory T cells (CD8 + /CD62L − CD44 + ) (Fig. S3) , indicating a polarization of antigen-specific T cells during expansion.
Lymph node injection of soluble vaccines promotes efficient expansion of Trp2 specific T cells, and co-delivery of high doses of Rapa MPs with vaccines suppresses T cell expansion
We recently developed a unique approach for controlling the combinations and concentrations of immune signals in LNs using intra-LN injection (i.LN.) of degradable, diffusion-limited microparticles. [26, [29] [30] [31] [32] This idea builds on recent clinical trials exploring i.LN. injection of soluble antigens in the context of allergies and cancer. [33] [34] [35] [36] Since LNs are key sites where T cells develop, and in particular, pro-inflammatory T cells develop in tumor draining-LNs, [24] we reasoned this platform might allow direct investigation of local Rapa release during vaccine introduction and differentiation of T cells. We first compared the efficacy of LN injection to intra-muscular injection (i.m.), a common peripheral vaccination route. In these studies, mice were injected i.m. or i.LN. with a soluble vaccine consisting of soluble CpG mixed with soluble Trp2 peptide. The Trp2 peptide is a common, conserved human melanoma-associated antigen. [28] Fourteen days after vaccination, Trp2 specific T cells were quantified in peripheral blood using MHC-I tetramer staining. Vaccines delivered with i.LN. injection promoted significantly higher frequencies of Trp2 specific T cells compared to vaccines delivered i.m., which promoted no detectable T cell response (Fig. 6A) . Therefore, all further vaccine studies utilized i.LN. injection. To determine if localized co-delivery of Rapa MPs with soluble vaccines to LNs could enhance T cell response, mice were primed i.LN. with soluble vaccines (Trp2 + CpG) alone or soluble vaccines mixed with Rapa MPs (soluble CpG + soluble Trp2 + Rapa MP high). 15 days after the priming vaccine, mice were boosted s.c. at the tail base (Fig. 6B ). Increased Trp2 specific T cell frequencies in peripheral blood were observed one week after the prime in the mice treated with the soluble vaccine, while the inclusion of Rapa MPs at this (high) dose suppressed the expansion of Trp2 specific T cells to levels similar to those measured in untreated mice (Fig. 6C) . Tetramer levels for the soluble vaccine treated group then contracted to levels similar to untreated mice by 14 days after the prime (Fig. 6D ). However, a recall response was observed in mice treated with soluble vaccines while again no detectable response was detected in mice treated with soluble vaccines + Rapa MPs. 6 days after the boost (day 21 post prime) the soluble vaccine treated group had an average Trp2 tetramer frequency of 4.14 ± 1.44% compared to 0.37 ± 0.04% in mice treated with the soluble vaccine + Rapa MPs (Fig. 6E) . These results suggested that local LN delivery of Rapa MPs at this dose suppressed responses to of soluble vaccine components (i.e., peptide + adjuvant). After challenge with B16-F10 tumors, no differences in survival were observed between untreated mice and mice vaccinated with soluble vaccines alone or vaccines combined with high dose rapa MPs (Fig. 6F ).
i.LN. co-delivery of Rapa MPs with soluble vaccines enhances expansion of Trp2 specific T cells
In order to determine if a lower dose of Rapa MPs could enhance T cell responses when combined with i.LN. vaccination, mice were vaccinated i.LN. with soluble vaccines or soluble vaccines mixed with Rapa MPs at half of the dose which suppressed T cell responses in the previous study (Fig. 6) . Further, these Rapa-loaded particles were administered only during the priming injection phase during which naïve T cells differentiate. Mice were primed on day 0 with the indicated treatments, then boosted with simple soluble vaccines (i.e., no Rapa MPs) s.c. at the tail base on day 15, 57 and 97 (Fig. 7A) . Interestingly, while both soluble vaccines and soluble vaccines + Rapa MPs promoted expansion of Trp2 specific T cells, tetramer frequencies were elevated throughout the duration of the study following the first boost in the soluble vaccine + Rapa MP treated group compared to mice receiving vaccine without Rapa MPs (Fig. 7B) . Soluble vaccines promoted a significant expansion of Trp2 specific T cells 7 days after the prime ( Fig. 7C) , while at Day 7, soluble vaccines co-delivered with Rapa MPs promoted only a modest expansion. Tetramer frequencies contracted to similar levels observed in untreated mice by day 14 (Fig. 7B) . Strikingly, despite the lower levels observed during the primary response at day 7, an increased recall response was observed after the boost in mice primed with soluble vaccines combined with Rapa MPs. At day 21, an average tetramer frequency of 4.56 ± 1.14% was observed in the soluble vaccine + Rapa MP group, compared to 3.19 ± 0.81% in the soluble vaccine treated group (Fig. 7C) . Tetramer levels for soluble vaccine and soluble vaccine + Rapa MP groups contracted to similar levels by the second boost at day 57 (Fig. 7B) , and again a larger recall response was observed in the soluble vaccine + Rapa MP group compared to the soluble vaccine group after the second boost (Fig. 7C) . At this time point, the enhancement from inclusion of Rapa depots reached as high as 26.1% of CD8 + T cells in peripheral blood specific for Trp2, compared to a maximum frequency of 8.1% in mice receiving the same vaccine without Rapa (Fig. 7D) (Fig. 7E ). These modest effects, however, were not statistically significant for tumor burden (p = 0.111) or survival (p = 0.1884) comparing mice treated with soluble vaccines ± Rapa MPs (Fig. 7F ).
i.LN. Delivery of Rapa MPs with soluble vaccines expands antigenspecific T CM
Since robust anti-tumor efficacy was not observed in mice treated with Trp2 vaccines combined with lose dose Rapa MPs, despite increased levels of cytotoxic T cells, we used a simpler regimen and a well-defined antigen to directly investigate polarization of central memory T cells. In these studies, mice were vaccinated i.LN. with soluble CpG and a model antigen, Ovalbumin (OVA), with or without low dose Rapa MPs. Booster injections were not administered to simplify the studies. Fourteen and twenty one days after vaccination, the frequency of CD8 + T cells specific for an immunodominant CD8 epitope of OVA-SIINFEKL (SIIN)-was assessed by MHC-I tetramer staining, along with the level of SIIN-specific CD8 + T CM (CD44 + CD62L + ) (Fig. 8A) . By fourteen days post vaccination, OVA vaccines combined with Rapa MPs increased SIIN-specific T cells, with 4.35 ± 0.37% of CD8 + T cells specific for SIIN, compared to 3.00 ± 0.22% in mice immunized with OVA vaccines alone (Fig. 8B) . Further, phenotypic analysis revealed that inclusion of Rapa MPs in the vaccine led to a 60% increase (p b 0.01) in the frequency of OVA-specific T CM cells by day 14 (Fig. 8C) . At day 21 after immunization, similar trends were observed for both tetramer frequencies and T CM levels (Fig. 8B,C ), but these differences were not significant. Since Rapa MPs promoted antigen-specific central memory T cells when combined with a model antigen, we next determined if these effects occurred with vaccines integrating Trp2 antigen. Mice were vaccinated i.LN. using an identical regimen as just described for OVA (Fig. 8A) , but OVA was replaced with Trp2 peptide in each group. At day 14 after vaccination, Trp2 tetramer frequencies among CD8 + T cells increased similarly for groups vaccinated with or without Rapa MPs. By day 21, however, vaccines including Rapa MPs drove Trp2-specific T cell levels that were 40% higher compared to vaccines lacking the Rapa MPs (Fig. 8D) . Interestingly, at day 14, when Trp2 tetramer frequencies were similar for both treatment groups, T CM analysis revealed low dose Rapa MP treatment promoted a 36% increase in the frequency of Trp2-specific T CM compared with mice receiving only the vaccine. (Fig. 8E ). This trend was also observed at day 21 after vaccination, where the frequency of Trp2-specific T CM was significantly higher in the Rapa MP treated group compared to mice receiving only vaccines ( Fig. 8E) . To investigate if Rapa MPs polarized differentiation toward T CM , the ratio of T CM to T EFF (CD44 + CD62L − ) among Trp2 specific T cells was analyzed. At both day 14 and day 21, the ratio of T CM to T EFF revealed a bias toward increased T CM :T EFF in the low dose Rapa MP group, although the level of significance was weaker for day 14 (p = 0.051) and day 21 (p = 0.057) (Fig. 8F ).
Discussion
Regulating mTOR or other metabolic pathways offers new potential for tuning immune response by controlling plasticity to alter the phenotype and function of differentiating cells [37, 38] . Rapamycin, although, conventionally an immunosuppressant, is already used in cancer therapy, along with a number of structural analogs ("Rapalogs") [17] [18] [19] . mTOR has two key signaling centers, mTORC1, and mTORC2, and many rapalogs seek to block both of these to limit the uncontrolled growth of tumor cells. With respect to vaccination, new studies are being carried out to see if Rapa might serve the more subtle role we have investigated, as an immunoregulatory signal. The distinguishing features of this idea are that the doses are low, and that Rapa or other drugs are delivered in the presence of an adjuvant (compared with a traditional immunosuppressant application lacking pro-immune signals). For example, in infectious disease, several recent studies have used daily dosing of Rapa to promote T CM [7, 8] , and in particular, demonstrate that early exposure to Rapa during T cell priming promotes increased IL-12 production that drives the improvements in durability and proliferative capacity (i.e., biasing toward T CM ) [20] . These effects also conferred a protective effect during live bacterial challenge with Listeria monocytogenes.
The finding above is interesting, as in our studies Rapa could be used to drive IL-12 expression in a dose dependent manner when released from particles. Our in vitro studies revealed a suppressive effect on some aspects of DC function at high doses, while at decreasing doses this effect was reversed, promoting inflammatory function. In particular, the 1 μg/mL dose of Rapa MPs decreased IFNγ without impacting IL-12, but when the Rapa MP dose decreased, IL-12 (and IL-6 to a lesser level) spiked beyond above levels induced by LPS stimulation alone. IL-12 is a key cytokine that signals T cell differentiation and proliferation. Another interesting aspect of our studies is that at doses where Rapa MPs didn't affect DC activation or inflammatory cytokine secretion, these MPs still decreased T cell proliferation in culture. Additionally, at doses where Rapa MPs caused decreases in DC activation (Fig. 2,  Fig. S1 ), and increases in pro-immune cytokine secretion (Fig. 3B,C) , Rapa MPs still partially attenuated T cell proliferation in both CD4 + and CD8 + T cell co-cultures. This reduction in proliferation may potentially be attributed to effects of Rapa MPs directly -at least partially -on T cell function, independent from the modulatory effects on DCs. This explanation is consistent with findings from Araki et al. which demonstrate Rapa promotes central memory phenotypes in vivo when combined with LCMV challenge through a mechanism dependent on the inhibition of mTORC2 in T cells [7] . These differing effects of Rapa MPs on DCs and T cells observed in vitro may have important implications for the i.LN. vaccine platform we utilized in vivo. Rapa MPs are formulated at a size which is readily internalized by APCs (Fig. 1E) , providing a simple mechanism to target encapsulated drug to DCs. We have previously shown that MPs formulated similarly are retained in LNs over time, resulting in prolonged localized increases in concentrations of encapsulated cargo. Therefore this system may function as an efficient method to target DCs for enhanced immunostimulatory function, while Rapa MPs remain extracellularly to provide controlled release and locally exert additional immunomodulatory effects on T cells during priming in the LNs when co-delivered with vaccines. In our cell culture studies, free Rapa was generally more potent than Rapa MPs, however, these formulations clearly provide different drug availability and kinetics. In vivo, these considerations are significant since free drug is hydrophobic, exhibits a short half-life, and risks broad suppression if delivered in an uncontrolled or untargeted way.
To address these problems, we used i.LN. delivery of depots loaded with Rapa as a means of directly testing the effect on T cell function. Several recent papers have explored regular administration of free Rapa during cancer vaccination, and one in particular has used i.LN. administration [22] . In this report free CpG and mRNA encoding antigen were administered to inguinal LNs, while Rapa was injected daily by i.p. injection. This approach improved survival, and interestingly -as with other reports [7] -the effect on T cell polarization depended on when the drug was delivered.
Our in vitro studies with CD8 + T cells revealed proliferation was reduced in Trp2 T cell co-cultures (Fig. 5A,B) , but their phenotype was polarized toward central memory (Fig. 5E,F) . These effects may allow for reduced T cell contraction and rapid proliferation after re-exposure to antigen, which could enhance T cell responses during vaccination in vivo. Our animal studies support this idea: low dose Rapa MPs combined with soluble vaccines initially (i.e., day 7) reduced T cell expansion after the prime compared to soluble vaccines alone (Fig. 7C ), but the recall response after subsequent boosts was larger and faster in the Rapa MP treated group. For example, Trp2 tetramer levels contracted to similar levels for soluble vaccine and soluble vaccine + Rapa MP treated mice at 14 days after the prime (Fig. 7B) (1 day before the first boost), but expansion of Trp2 specific T cells was significantly higher on days 21 and 64 (one week after booster injections) for the soluble vaccines + Rapa MPs group (Fig. 7B, C) . The increased expansion after the boost supports the hypothesis that low dose Rapa MPs tune T cells to phenotypes with superior proliferative capacity. During analysis of memory phenotype, we discovered that the addition of Rapa MPs enhanced the level and persistence of T CM . There are several implications from these studies. First, we observed similar or increased levels of antigen-specific T cells, as well as an increase in the frequency of circulating antigen-specific T CM cells (Fig. 8) . Both of these effects correlated with addition of the Rapa MP component to the vaccines. These two observations might indicate functionality of T CM that led to the increased expansion of Trp2-specific T cells measured in the boosting and recall studies (Fig. 7) . For example, the data in Fig. 7B at Day 14 (just before the first boost) revealed similar levels of Trp2-specific T cells, but a large expansion the following week after boost when comparing groups receiving vaccine + Rapa MPs as the priming regimen to groups receiving only the vaccine. At this equivalent time in Fig. 8B , although the tetramer levels were similar, the frequency of T CM and T CM :T EFF were significantly higher in the groups receiving the vaccine with Rapa MPs. Together this set of results supports the idea that local co-administration of low dose Rapa MPs with soluble vaccines polarizes T CM phenotypes to enhance T cell response. As discussed below, however, although Rapa MPs polarized T CM , these effects did not translate to potent anti-tumor immunity.
Our own results and the literature reports discussed above highlight an important role for both dose and kinetics in the proposed strategy. For example, past work reveals that repeated treatment during the priming T cell expansion phase leads to more durable T cell responses, while daily treatment during only the T cell contraction phase leads polarizes cells toward central memory [7] . Regular treatment during both phases provides both durability and improved memory function. At the same time, other studies in models such as human papilloma viruses, indicate Rapa does not provide protective effects and may be suppressive [39] . Thus, there is great potential for biomaterials in this area, both to enable new therapies, but also as tools to understand the impact of kinetics and dosing of drug delivery on mTOR signaling, and ultimately on T cell fate. For example, could tunable release kinetics be used to target only the expansion or only the contraction phase, and thus program durability/maintenance, polarization to T CM , or both?
In our studies, the expansion of T cells generated by incorporation of Rapa MPs provided only a modest impact during tumor challenge (Fig. 7G,H) , though we used an aggressive metastatic melanoma model. In the clinic, cancer vaccines are extremely unlikely to be used as monotherapies, but instead will be coupled with checkpoint blockagewhere natural immune regulatory pathways are blocked, with proimmune cytokines, or with other combination therapies [9] . Thus, while we measured greater expansion of tumor-specific T cells but limited efficacy, there are a variety of potential strategies which may function to enhance the anti-tumor function of T cells generated by vaccines combining metabolic modulators. In particular, checkpoint blockade is creating a renaissance for cancer vaccines using anti-CTLA4 or anti-PDL1 monoclonal anti-bodies that could be combined with vaccines and Rapa MP treatments to inhibit exhaustion of T cells driven by tumor evasion mechanisms. In addition it is possible that limited antitumor effectiveness we observed may be due in part to the use of a vaccine containing a single tumor antigen. Applying Rapa MPs to enhance T cell response toward broad sets of tumor-associated antigens, including multiple well-defined antigens or tumor cell lysates which contain highly immunogenic neoantigens, may serve as a potential strategy to significantly enhance anti-tumor immunity. As these strategies develop, there will also be important safety questions already facing some of the developing technologies. For example, how to balance the risk/reward profile of giving an immunosuppressant, or how to "turn-off" the effects of checkpoint blockage or greatly enhance proliferation during Rapacontaining vaccines therapies that may arise. Despite these hurdles, here we demonstrate an exciting new biomaterial-enabled strategy to program the local LN microenvironment for polarizing the phenotypes of developing T cells that could contribute to new options in for vaccines against infectious disease and for cancer immunotherapies.
Conclusion
In this study, we utilized a well-studied controlled release platform to investigate how the presence of low doses of a common regulatory drug alters the nature of immune response during vaccination with peptide antigens and molecular agonists. Rapa MPs reduced -but did not stop -DC activation and T cell proliferation. These effects were dose-dependent, and could be switched between suppression and enhancing functions, the latter resulting from polarization of antigenspecific T cells toward central memory function. Although only modest functional effects were observed during an aggressive tumor challenge, this report demonstrates the intriguing potential of using controlled release during vaccination to preserve T cells plasticity and enhance T cell function. In particular, this ability might enable new, simpler approaches to recapitulate the attractive features of adoptive cell therapies that currently require isolation from patients, expansion, and reinfusion to generate sufficient numbers of cells for efficacy.
